PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm
news

Two cancer cell therapy studies succeeded. Why did a third fail?

In two major clinical trials, researchers found cell therapy dramatically outperformed the standard of care used for the past few decades to counter a common type of ...
Continue Reading →
news

A startup led by Novartis veteran raises $80M to develop gene therapies for the brain

The U.K. startup has aims to improve on neurodegenerative therapy by using technology developed in a King's College laboratory run by Christopher Shaw. Shaw is a co-f...
Continue Reading →
news

Novartis to consider sale or separation of Sandoz business

Under CEO Vas Narasimhan, Novartis has slimmed down what was a sprawling conglomerate spanning prescription and generic drugs, eye care and consumer healthcare. The d...
Continue Reading →
news

Novartis finalizes deal to make new heart drug widely available in England

Novartis has made a big bet on Leqvio and now the U.K. government has, too, motivated by the prevalence of heart disease and its strong links to high cholesterol. Leq...
Continue Reading →
news

Sarepta adds another gene therapy to its ever-expanding pipeline

Sarepta can claim one of the larger pipelines in biotech, with 42 different programs listed by the developer. Twenty-six of those are gene replacement therapies for a...
Continue Reading →
news

Novartis picks up IL-17 inhibitor in deal worth over $1B

Novartis on Thursday inked a deal for development and commercialization rights to MOR106, an interleukin (IL)-17C inhibitor for the treatment of atopic dermatitis ...
Continue Reading →
news

Amgen, Novartis’ closely watched migraine drug approved

Amgen and Novartis on Thursday secured Food and Drug Administration approval for Aimovig, the first regulatory thumbs up for a new class of migraine treatments ca...
Continue Reading →

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC